Rakesh Popat
University College London Hospitals NHS Foundation Trust
Internal medicineSurgeryOncologyAdverse effectLenalidomideMultiple myelomaNeutropeniaBortezomibTolerabilityAutologous stem-cell transplantationVenetoclaxCarfilzomibDexamethasoneRegimenPopulationTransplantationIn patientRelapsed refractoryRefractoryCancer researchClinical trialMedicine
131Publications
20H-index
1,062Citations
Publications 134
Newest
#1Graham P. CollinsH-Index: 24
Source
#1Wei Yee Chan (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
#2Nicholas CounsellH-Index: 22
view all 21 authors...
Source
#1Wei Yee Chan (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
#2Lara Howells (UCLH: University College London Hospitals NHS Foundation Trust)
Last. K. Xu (UCLH: University College London Hospitals NHS Foundation Trust)
view all 22 authors...
Source
#1Rakesh Popat (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 20
#2William R. Wilson (UCL: University College London)H-Index: 70
Last. Karthik Ramasamy (University of Oxford)H-Index: 19
view all 22 authors...
Background null The role of upfront ASCT for NDTE MM remains under evaluation with high MRD rates following novel induction and consolidation (cons) strategies. K maintenance represents an alternative strategy to lenalidomide maintenance. The CARDAMON trial investigated K maintenance following KCd induction plus either ASCT or KCd cons. null null null Methods null NDTE pts received 4 x KCd induction (K 20/56 mg/m2 biweekly, C 500 mg D 1,8,15, d 40mg weekly) before 1:1 randomisation to ASCT or 4 ...
Source
#1Wei Yee Chan (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
#2Lara Howells (UCLH: University College London Hospitals NHS Foundation Trust)
Last. Annabel McMillan (Whittington Hospital)
view all 22 authors...
Background null Concerns have been raised about the ability of patients with plasma cell disorders (PCD) to mount adequate immune responses to vaccination, particularly considering the initial extension to vaccination intervals in the United Kingdom to up to 12 weeks in December 2020, the start of the vaccination roll-out. Protecting this vulnerable patient group with anti-SARS-CoV-2 vaccination is critical. null Methods null We measured the humoral responses in PCD patients after the first dose...
Source
Source
#1Sagar Lonial (Emory University)H-Index: 102
#2Paul G. Richardson (Harvard University)H-Index: 208
Last. Ashraf Z. Badros (University of Maryland Medical Center)H-Index: 15
view all 18 authors...
Background null CC-220-MM-001 (NCT02773030) is an ongoing phase 1/2 study evaluating the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, and preliminary efficacy of IBER, an oral, novel cereblon E3 ligase modulator (CELMoD®) compound, with different treatment combinations in independent cohorts, in pts with MM. Here we report results from the IBER+DARA+DEX (IberDd), IBER+BORT+DEX (IberVd), and IBER+CFZ+DEX (IberKd) cohorts in RRMM. null null null Methods null Eligible pts receiv...
Source
#1Annabel McMillan (Whittington Hospital)
Last. Neil Rabin (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 14
view all 13 authors...
Background null Achieving minimal residual disease (MRD) negativity during treatment for multiple myeloma (MM) is prognostic for disease free and overall survival. There is limited testing of MRD outside clinical trials, and the need to process fresh samples for multicolour flow cytometry (MCF) assays presents a challenge to laboratories. We set up an 8-colour MCF assay, in collaboration with a reference centre (Leeds HMDS), to identify and quantify malignant plasma cells in bone marrow (to limi...
Source
#1Thibaud PrawitzH-Index: 4
#2Rakesh Popat (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 20
Last. Jenny Willson (GSK: GlaxoSmithKline)H-Index: 3
view all 11 authors...
Single-agent belantamab mafodotin (belamaf; BLENREP) demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma and ≥ 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody (DREAMM-2; NCT03525678). At the time of this study, STORM Part 2, NCT02336815 (selinexor plus low-dose dexamethasone; sel + dex) was systematically identified as the only feasible comparator to the DREAMM-2 cohort. Matching-adjusted indire...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.